Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1701288

	registered interest
	date	16/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Lung Cancer: Public Health
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether she has made a recent assessment of the effectiveness of the help us, help you campaign.
	tabling member constituency	East Londonderry
	tabling member printed	Mr Gregory Campbell
	uin	21912
	answer	answer is ministerial correction date of answer 19/04/2024 answer text <p>No recent assessment has been made. In 2020 NHS England launched the Help Us, Help You (HUHY) campaigns, a major public information campaign to persuade the public to seek urgent care and treatment when they needed it. The HUHY campaign strategy is designed to address the underlying barriers to cancer diagnosis, including multifaceted fears and a lack of body vigilance, along with the lack of knowledge of cancer symptoms, to encourage people to present earlier.</p><p>On 8 January 2024, NHS England relaunched the HUHY campaign for cancer, designed to increase earlier diagnosis of cancer by reducing barriers to seeking earlier help, as well as increasing body vigilance and knowledge of key red flag symptoms. This campaign addresses barriers to people coming forward with suspected signs of cancer in general, and is not specific to screening or cervical cancer.</p><p>We are seeing continued high levels of urgent cancer referrals, which suggests the HUHY campaigns continue to be effective. Over 12,000 urgent referrals were seen for suspected cancer per working day in February 2024, compared to approximately 9,000 in January 2020.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 19/04/2024 07:32:51 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	1409 label Biography information for Mr Gregory Campbell

1701290

	registered interest
	date	16/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what estimate she has made of the number and proportion of NHS providers that have adopted two stage shared decision-making across all admitted pathways.
	tabling member constituency	Bristol South
	tabling member printed	Karin Smyth
	uin	22045
	answer	answer is ministerial correction date of answer 19/04/2024 answer text <p>In May 2023, NHS England published guidance setting out five core perioperative care requirements relating to the care of adult patients awaiting planned inpatient surgery. One of these requirements is that patients must be involved in shared decision making regarding admitted pathways. NHS England does not collect data on the number of National Health Service providers that have adopted two stage shared decision making across all admitted pathways. NHS England’s published guidance is available at the following link:</p><p><a href="https://www.england.nhs.uk/long-read/earlier-screening-risk-assessment-and-health-optimisation-in-perioperative-pathways/#2-five-core-requirements-for-providers" target="_blank">https://www.england.nhs.uk/long-read/earlier-screening-risk-assessment-and-health-optimisation-in-perioperative-pathways/#2-five-core-requirements-for-providers</a></p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 19/04/2024 09:58:11 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4444 label Biography information for Karin Smyth

1701292

	registered interest
	date	16/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Nurses: Training
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many training places for district nurses her Department plans to make available in September 2025.
	tabling member constituency	Bristol South
	tabling member printed	Karin Smyth
	uin	22047
	answer	answer is ministerial correction date of answer 19/04/2024 answer text <p>The NHS Long Term Workforce, published on 30 June 2023, sets out an ambition to increase the number of district nursing training places to 842 in 2025.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 19/04/2024 07:34:01 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4444 label Biography information for Karin Smyth

1701024

	registered interest
	date	15/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Incontinence: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if she will make it her policy to make an assessment of the potential impact of any proposed amendments to Part IX of the Drug Tariff on (a) patients with continence care needs, (b) continence care services, (c) the range of continence devices available to clinicians and patients and (d) new product development and innovation in medical devices in the continence sector.
	tabling member constituency	Stockport
	tabling member printed	Navendu Mishra
	uin	21863
	answer	answer is ministerial correction date of answer 18/04/2024 answer text <p>Part IX will remain a list of devices available to be prescribed in the community, via the FP10 prescription route. The Department believes that it is currently difficult to identify which devices are broadly comparable, and whether more expensive devices provide added value. The proposed amendments that were consulted on were intended to increase meaningful choice, not to decrease the choice for clinicians and patients. Comparison between products can increase awareness of different brands amongst prescribers, which can support small and medium sized businesses in entering the market.</p><p>The consultation response on the proposed amendments to Part IX is expected to be released in May 2024, which will outline the Government’s response. Any amendments that are taken forward will happen gradually, with review points and engagement with stakeholders, including industry, patient representatives, clinicians, and National Health Service organisations. We are aware that there are some very good devices in use, relied upon by clinicians and patients.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 18/04/2024 09:34:23 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4811 label Biography information for Navendu Mishra

1701026

	registered interest
	date	15/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Bowel Cancer: Greater Manchester
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent assessment her Department has made of the adequacy of bowel cancer diagnosis services in (a) Stockport and (b) Greater Manchester.
	tabling member constituency	Stockport
	tabling member printed	Navendu Mishra
	uin	21865
	answer	answer is ministerial correction date of answer 18/04/2024 answer text <p>The Department continues to take steps to improve early diagnosis for all cancers, which encompasses bowel cancer, and in all areas, including Stockport and Greater Manchester. The Department is working jointly with NHS England on implementing the Delivery Plan for Tackling the COVID-19 Backlog of Elective Care, which includes plans to spend more than £8 billion from 2022/23 to 2024/25 to help drive up and protect elective activity, including cancer diagnosis and treatment.</p><p>NHS England is working to meet the Faster Diagnosis Standard (FDS), which sets a target of 28 days from urgent referral by a general practitioner or screening programme to patients being told that they have cancer, or that cancer is ruled out. To achieve this target, NHS England has: streamlined bowel cancer pathways by implementing faecal immunochemical testing (FIT) triage for patients in primary and secondary care settings; implemented non-symptom specific pathways for patients; and opened community diagnostic centres across England, prioritising this capacity for cancer services. The latest published data from February 2024 shows FDS performance was 78.1% nationally. More specifically to bowel cancer, the latest published data shows that at a national level, the number of people diagnosed with bowel cancer has risen to 41,596 in 2021, compared to 37,702 diagnosed in 2019. Since the FIT kit was introduced into the bowel cancer screening programme in April 2019, national uptake has increased from 59.2% to 67.8%. the latest data for the North-West region shows that 64.3% of 60 to 74-year-olds completed their bowel screening in the first quarter of 2023/24.</p><p>In 2023 the NHS England’s Help Us Help You campaign urged people to take up the offer of bowel screening when invited, and the screening offer for the bowel screening programme is being gradually extended from age 60 down to 50 years old by 2025, ensuring more people are screened and potentially diagnosed with bowel cancer at the earliest stage.   NHS England is also now offering routine preventative bowel cancer screening to people with Lynch syndrome, with 94% of people on average receiving the test between 2021 and 2023, up from 47% in 2019.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 18/04/2024 09:37:22 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4811 label Biography information for Navendu Mishra

1699968

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pharmacy: Finance
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential impact of medication costs on community pharmacies.
	tabling member constituency	Gosport
	tabling member printed	Dame Caroline Dinenage
	uin	20988
	answer	answer is ministerial correction date of answer 19/04/2024 answer text <p>Through the medicine margin survey, the Department assesses whether the reimbursement arrangements pay pharmacy contractors as agreed as part of the community pharmacy contractual framework (CPCF). The medicine margin survey considers what pharmacies paid for medicines by looking at their invoices compared to the amount reimbursed by the National Health Service. Where the survey finds that they have been underpaid, we increase the pharmacy contractors’ payments, and where they have been overpaid, we decrease payments.</p><p>Furthermore, where pharmacies cannot purchase products at or below the Drug Tariff NHS reimbursement price, Community Pharmacy England can request that the Department reassesses the reimbursement price. If a new reimbursement price is issued, this is known as a concessionary price.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20979 question first answered 19/04/2024 09:54:36 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4008 label Biography information for Dame Caroline Dinenage

1699978

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Diabetes: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential impact of discontinuing funding for T1DE pilot schemes on the health and well-being of patients living with type 1 diabetes with disordered eating.
	tabling member constituency	Knowsley
	tabling member printed	Sir George Howarth
	uin	20895
	answer	answer is ministerial correction date of answer 18/04/2024 answer text <p>NHS England has provided funding for eight integrated care boards (ICBs) across the country to support the development and establishment of Type 1 Diabetes with Disordered Eating (T1DE) services in every National Health Service region. Funding has been provided on a pump prime basis, and the responsibility for the longer-term sustainable provision of care for these patients sits with the relevant integrated care system.</p><p>A nationally commissioned evaluation has shown the positive impact that the provision of T1DE services can have for patients, including reductions in HbA1c, which is linked to reduced rates of diabetes complications, and reduced rates of emergency admissions.</p><p>It’s the role of the ICBs to consider the health needs of their populations, in making decisions about the care that is provided. It is expected that ICB leads consider these evaluation findings alongside the risk to patient health and wellbeing of the discontinuation of service provision, as well as other local contextual factors in making decisions about the future provision of T1DE services.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 18/04/2024 12:53:21 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	481 label Biography information for Sir George Howarth

1699979

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Diabetes: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment her Department has made of the potential implications for its policies of the cost-benefit analysis of the T1DE pilot schemes carried out by NHS England.
	tabling member constituency	Knowsley
	tabling member printed	Sir George Howarth
	uin	20896
	answer	answer is ministerial correction date of answer 17/04/2024 answer text <p>Evaluation by the National Health Service of the initial Type 1 Diabetes with Disordered Eating service (T1DE) pilot sites, in London and Wessex, demonstrated a mean reduction in HbA1c of between 2.3% to 2.5%. Assuming that this level of reduction is maintained, the lifetime quality-adjusted life year gain of these services was estimated at 1.49, which would be cost effective up to a net lifetime cost of £29,800-£44,800.</p><p>In response to these initial evaluation findings, NHS England expanded the T1DE programme, supporting provision of new services in an additional five sites from September 2022, expanding coverage to more areas of the country. It is expected that these services will generate further evaluation data to consolidate these early findings, which can be used to inform national and local policy decisions.</p><p>NHS England is drawing on learning from existing T1DE services, other emerging evidence and the findings of the recent parliamentary inquiry, to ensure all areas of the country are supported to improve care for those identified as having T1DE. The emergence of these future plans are subject to future spending review settlements for the NHS and level of funding from the NHS England budget allocated to T1DE.</p><p>NHS England are also working closely with the first wave of pilot sites including London to ensure that the newer services can benefit from their learning and experience when considering local funding options in advance of March 2025, when the national funding for the five new sites will come to an end.<strong><br> </strong></p><p>NHS England is assisting integrated care boards to develop local funding arrangements through the provision of evaluation data, a national programme of support workshops, and an online platform to share learning and good practice.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20897 question first answered 17/04/2024 15:22:42 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	481 label Biography information for Sir George Howarth

1699980

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Diabetes: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether she (a) has made and (b) plans to make an assessment of the potential merits of funding options to ensure the sustainability of T1DE services beyond the pilot phase.
	tabling member constituency	Knowsley
	tabling member printed	Sir George Howarth
	uin	20897
	answer	answer is ministerial correction date of answer 17/04/2024 answer text <p>Evaluation by the National Health Service of the initial Type 1 Diabetes with Disordered Eating service (T1DE) pilot sites, in London and Wessex, demonstrated a mean reduction in HbA1c of between 2.3% to 2.5%. Assuming that this level of reduction is maintained, the lifetime quality-adjusted life year gain of these services was estimated at 1.49, which would be cost effective up to a net lifetime cost of £29,800-£44,800.</p><p>In response to these initial evaluation findings, NHS England expanded the T1DE programme, supporting provision of new services in an additional five sites from September 2022, expanding coverage to more areas of the country. It is expected that these services will generate further evaluation data to consolidate these early findings, which can be used to inform national and local policy decisions.</p><p>NHS England is drawing on learning from existing T1DE services, other emerging evidence and the findings of the recent parliamentary inquiry, to ensure all areas of the country are supported to improve care for those identified as having T1DE. The emergence of these future plans are subject to future spending review settlements for the NHS and level of funding from the NHS England budget allocated to T1DE.</p><p>NHS England are also working closely with the first wave of pilot sites including London to ensure that the newer services can benefit from their learning and experience when considering local funding options in advance of March 2025, when the national funding for the five new sites will come to an end.<strong><br> </strong></p><p>NHS England is assisting integrated care boards to develop local funding arrangements through the provision of evaluation data, a national programme of support workshops, and an online platform to share learning and good practice.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20896 question first answered 17/04/2024 15:22:42 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	481 label Biography information for Sir George Howarth

1700007

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pharmacy: Finance
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment she has made of the adequacy of the medication reimbursement mechanism for community pharmacists.
	tabling member constituency	Easington
	tabling member printed	Grahame Morris
	uin	20979
	answer	answer is ministerial correction date of answer 19/04/2024 answer text <p>Through the medicine margin survey, the Department assesses whether the reimbursement arrangements pay pharmacy contractors as agreed as part of the community pharmacy contractual framework (CPCF). The medicine margin survey considers what pharmacies paid for medicines by looking at their invoices compared to the amount reimbursed by the National Health Service. Where the survey finds that they have been underpaid, we increase the pharmacy contractors’ payments, and where they have been overpaid, we decrease payments.</p><p>Furthermore, where pharmacies cannot purchase products at or below the Drug Tariff NHS reimbursement price, Community Pharmacy England can request that the Department reassesses the reimbursement price. If a new reimbursement price is issued, this is known as a concessionary price.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20988 question first answered 19/04/2024 09:54:35 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	3973 label Biography information for Grahame Morris

1700034

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Trastuzumab Deruxtecan
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if she will make a comparative assessment of the adequacy of the reasons the (a) National Institute for Health and Care Excellence has been unable and (b) Scottish Medicines Consortium has been able to recommend Enhertu for use on the NHS.
	tabling member constituency	Brighton, Pavilion
	tabling member printed	Caroline Lucas
	uin	20959
	answer	answer is ministerial correction date of answer 16/04/2024 answer text <p>The National Institute for Health and Care Excellence (NICE) makes authoritative, evidence-based recommendations for the National Health Service in England on whether new licensed medicines should be routinely funded by the NHS, based on an assessment of their costs and benefits. Decisions on the availability of medicines in Scotland are a matter for the devolved administration.</p><p>The NICE published guidance in 2021 and 2023 recommending Enhertu, also known as trastuzumab deruxtecan, for the treatment of NHS patients with HER2-positive breast cancer through the Cancer Drugs Fund, and it is now available to eligible NHS patients in England in line with the NICE’s recommendations.</p><p>The NICE is currently evaluating Enhertu for the treatment of metastatic HER2-low breast cancer, and has not yet published final guidance. Stakeholders have had an opportunity to appeal against the NICE’s draft recommendations, and the NICE will consider any appeals through the established process and publish final guidance in due course.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 16/04/2024 15:01:22 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	3930 label Biography information for Caroline Lucas

1700037

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Health Services: Consultants
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many and what proportion of NHS consultants carried out work in the private sector in the most recent financial year for which data is available.
	tabling member constituency	Knowsley
	tabling member printed	Sir George Howarth
	uin	20900
	answer	answer is ministerial correction date of answer 17/04/2024 answer text <p>The Department does not hold the information requested.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 17/04/2024 10:23:50 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	481 label Biography information for Sir George Howarth

1700039

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Disability Aids
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what data her Department holds on how many useable mobility aids and equipment are wasted in the NHS each year.
	tabling member constituency	Huddersfield
	tabling member printed	Mr Barry Sheerman
	uin	20866
	answer	answer is ministerial correction date of answer 17/04/2024 answer text <p>As set out in the Delivering a Net Zero National Health Service report, published in October 2020, the NHS is committed to reducing its environmental impact, including by increasing the reuse and recycling of medical equipment. This commitment is then applied locally, taking into account local priorities, through local Green Plans.</p><p>NHS England also collaborates with the NHS Supply Chain to increase availability of reusable products, and supports local NHS organisations through the publication of guidance and resources to help with implementing changes.</p><p>Furthermore, the Department published the inaugural Medical Technology Strategy in February 2023, which included a focus on improving resource efficiency. The Department’s Design for Life Programme works with industry, the health and care sector, and academic partners to develop medical technology systems that support reuse, remanufacture, and material recovery becoming the default. The Department recognises we will need to define future data requirements and align digital infrastructure to improve the gathering of core data, such as how products are eventually disposed. The Department’s intention is to publish a roadmap later this year, to articulate our relevant findings and plans moving forward.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20867 question first answered 17/04/2024 14:13:08 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	411 label Biography information for Mr Barry Sheerman

1700040

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Disability Aids: Waste Disposal
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what information her Department holds on where the NHS disposes of (a) crutches, (b) wheelchairs and (c) other mobility equipment.
	tabling member constituency	Huddersfield
	tabling member printed	Mr Barry Sheerman
	uin	20867
	answer	answer is ministerial correction date of answer 17/04/2024 answer text <p>As set out in the Delivering a Net Zero National Health Service report, published in October 2020, the NHS is committed to reducing its environmental impact, including by increasing the reuse and recycling of medical equipment. This commitment is then applied locally, taking into account local priorities, through local Green Plans.</p><p>NHS England also collaborates with the NHS Supply Chain to increase availability of reusable products, and supports local NHS organisations through the publication of guidance and resources to help with implementing changes.</p><p>Furthermore, the Department published the inaugural Medical Technology Strategy in February 2023, which included a focus on improving resource efficiency. The Department’s Design for Life Programme works with industry, the health and care sector, and academic partners to develop medical technology systems that support reuse, remanufacture, and material recovery becoming the default. The Department recognises we will need to define future data requirements and align digital infrastructure to improve the gathering of core data, such as how products are eventually disposed. The Department’s intention is to publish a roadmap later this year, to articulate our relevant findings and plans moving forward.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20866 question first answered 17/04/2024 14:13:08 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	411 label Biography information for Mr Barry Sheerman

1700068

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Trastuzumab Deruxtecan
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether NICE is taking steps to make Enhertu available to the National Health Service to treat incurable HER2-low secondary breast cancer.
	tabling member constituency	South Holland and The Deepings
	tabling member printed	Sir John Hayes
	uin	20865
	answer	answer is ministerial correction date of answer 16/04/2024 answer text <p>The National Institute for Health and Care Excellence (NICE) is currently developing guidance for the National Health Service on whether Enhertu can be recommended for routine NHS funding, based on an assessment of the costs and benefits. The NICE was unfortunately unable to recommend Enhertu as a clinically and cost-effective use of NHS resources in its final draft guidance published on 5 March 2024. Stakeholders have had an opportunity to appeal against the NICE’s draft recommendations, and the NICE will consider any appeals through the established process, and will publish final guidance in due course.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 16/04/2024 15:03:45 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	350 label Biography information for Sir John Hayes

1700149

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Lymphedema: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if she will make an assessment of the potential merits of providing lymphaticovenous anastomosis surgery on the NHS.
	tabling member constituency	Darlington
	tabling member printed	Peter Gibson
	uin	21204
	answer	answer is ministerial correction date of answer 18/04/2024 answer text <p>No formal assessment has been made of the potential merits of providing lymphaticovenous anastomosis surgery on the National Health Service. On 16 April 2024, the National Institute for Health and Care Excellence (NICE) published interventional procedures guidance that states that lymphovenous anastomosis during axillary dissection for preventing secondary lymphoedema in adults with breast cancer, can be used in the NHS while more evidence is generated, and that it can only be used with special arrangements for clinical governance, consent and audit, or research. The NICE’s interventional procedures guidance makes recommendations for the NHS on whether procedures are sufficiently safe and efficacious for use in routine clinical practice.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 18/04/2024 12:55:14 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4754 label Biography information for Peter Gibson

1700176

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Pay
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, for what reason NHS employees in band 4 are only eligible for pay progression after three years, rather than two years as in other bands.
	tabling member constituency	St Ives
	tabling member printed	Derek Thomas
	uin	21172
	answer	answer is ministerial correction date of answer 17/04/2024 answer text <p>As part of the 2018 deal, all pay bands underwent a significant amount of structural reform. The reform included reducing the length of time it takes to reach the top of most pay bands, improving pay progression, and removing all overlap between pay bands. As such, the time taken to progress to the top of Band 4 has been reduced from six years to three years. The time taken to progress varies by band. This is to reflect the time needed to develop the knowledge and skills to perform at the top of the relevant band.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 17/04/2024 08:59:44 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4532 label Biography information for Derek Thomas

1700217

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Maternity Services: Labour Turnover
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps her department is taking to improve retention rates of NHS maternity staff.
	tabling member constituency	Lewisham West and Penge
	tabling member printed	Ellie Reeves
	uin	21199
	answer	answer is ministerial correction date of answer 19/04/2024 answer text <p>The NHS Long Term Workforce Plan sets out how to improve culture and leadership, to ensure that up to 130,000 fewer staff leave the National Health Service over the next 15 years. This includes: implementing actions from the NHS People Plan that have been shown to be successful; implementing plans to improve flexible opportunities for prospective retirees, and delivering the actions needed to modernise the NHS pension scheme; and committing to ongoing national funding for continuing professional development for nurses, midwives, and allied health professionals, so NHS staff are supported to meet their full potential. These measures apply across staff groups, including maternity staff.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 19/04/2024 08:42:26 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4620 label Biography information for Ellie Reeves

1700242

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Atorvastatin: Shortages
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what discussions she has had with stakeholders on tackling shortages of atorvastatin.
	tabling member constituency	Ellesmere Port and Neston
	tabling member printed	Justin Madders
	uin	21098
	answer	answer is ministerial correction date of answer 19/04/2024 answer text <p>There have been supply issues with atorvastatin, but as a result of our work to manage those issues, including engaging with alternative suppliers to cover supply gaps in order to meet demand, they have now been resolved.</p><p> </p><p>The medicine supply chain is highly regulated, complex, and global. Supply disruption is an issue which affects the United Kingdom, as well as other countries around the world. There can be a variety of causes, including manufacturing issues, problems with access to raw ingredients, and sudden spikes in demand.</p><p> </p><p>Whilst we can’t always prevent supply issues, the Department has well-established tools and processes to manage them, in order to mitigate risks to patients. We work closely with the pharmaceutical industry, NHS England, the Medicines and Healthcare products Regulatory Agency, and others operating in the supply chain to help ensure patients continue to have access to suitable medicines when supply is disrupted.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 19/04/2024 10:15:51 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4418 label Biography information for Justin Madders

1700243

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Ezetimibe: Shortages
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what discussions she has had with relevant stakeholders on tackling shortages of Ezetimibe.
	tabling member constituency	Ellesmere Port and Neston
	tabling member printed	Justin Madders
	uin	21099
	answer	answer is ministerial correction date of answer 19/04/2024 answer text <p>The Department is aware of supply issues affecting several Ezetimibe suppliers. We are engaging with these suppliers to address the issues, and are working with alternative suppliers to ensure supplies remain available.</p><p>The medicine supply chain is highly regulated, complex, and global. Supply disruption is an issue which affects the United Kingdom, as well as other countries around the world. There can be a variety of causes, including manufacturing issues, problems with access to raw ingredients, and sudden spikes in demand.</p><p> </p><p>Whilst we can’t always prevent supply issues, the Department has well-established tools and processes to manage them, in order to mitigate risks to patients. We work closely with the pharmaceutical industry, NHS England, the Medicines and Healthcare products Regulatory Agency, and others operating in the supply chain to help ensure patients continue to have access to suitable medicines when supply is disrupted.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 19/04/2024 10:21:51 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4418 label Biography information for Justin Madders

1700244

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Etoricoxib: Shortages
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what discussions she has had with relevant stakeholders on tackling shortages of Etoricoxib.
	tabling member constituency	Ellesmere Port and Neston
	tabling member printed	Justin Madders
	uin	21100
	answer	answer is ministerial correction date of answer 19/04/2024 answer text <p>The Department is aware that a supplier of etoricoxib 60 milligram tablets is experiencing a supply issue. We have been working with that supplier to address the issue, and resupply is expected in early May 2024. We have worked with alternative suppliers to ensure they can cover the gap in the market in the meantime.</p><p>The medicine supply chain is highly regulated, complex, and global. Supply disruption is an issue which affects the United Kingdom, as well as other countries around the world. There can be a variety of causes, including manufacturing issues, problems with access to raw ingredients, and sudden spikes in demand.</p><p>Whilst we can’t always prevent supply issues, the Department has well-established tools and processes to manage them, in order to mitigate risks to patients. We work closely with the pharmaceutical industry, NHS England, the Medicines and Healthcare products Regulatory Agency, and others operating in the supply chain to help ensure patients continue to have access to suitable medicines when supply is disrupted.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 19/04/2024 10:11:19 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4418 label Biography information for Justin Madders

1700256

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Surgery: Finance
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how much elective recovery funding each integrated care board received less penalties for missed targets (a) in absolute terms and (b) as a proportion of the elective recovery funding initially allocated to the board, in financial year 2022/23.
	tabling member constituency	Ilford North
	tabling member printed	Wes Streeting
	uin	21155
	answer	answer is ministerial correction date of answer 17/04/2024 answer text <p>Each integrated care board (ICB) received their full elective recovery fund (ERF) allocation in 2022/23 and no penalties were applied for missing elective activity targets.</p><p>The initial ERF allocations for each ICB are available at the following link:</p><p><a href="https://www.england.nhs.uk/publication/allocation-of-resources-2022-23/" target="_blank">https://www.england.nhs.uk/publication/allocation-of-resources-2022-23/</a></p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 17/04/2024 17:18:24 answering member 4044 label Biography information for Andrew Stephenson previous answer version 28303 answering member constituency Pendle answering member printed Andrew Stephenson answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4504 label Biography information for Wes Streeting

1700279

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Chronic Fatigue Syndrome: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to ensure hospitals follow the NICE guidelines on Myalgic encephalomyelitis or chronic fatigue syndrome.
	tabling member constituency	Lancaster and Fleetwood
	tabling member printed	Cat Smith
	uin	21115
	answer	answer is ministerial correction date of answer 17/04/2024 answer text <p>It is the duty of clinicians to keep themselves appraised of best practice, in particular guidance issued by the National Institute for Health and Care Excellence (NICE). The Department is working with NHS England to develop an e-learning course on myalgic encephalomyelitis (ME), also known as chronic fatigue syndrome, for healthcare professionals, with the aim of supporting staff in providing better care and improving patient outcomes. This has involved feedback and input from the ME Research Collaborative Patient Advisory Group. The Medical Schools Council will promote the NHS England e-learning package on ME to all United Kingdom medical schools, and encourage medical schools to provide undergraduates with direct patient experience of ME. The NICE’s guidance NG206 states that people with ME should undertake a dietetic assessment by a dietitian with a special interest in ME, if they are losing weight and at risk of malnutrition.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 21116 question first answered 17/04/2024 14:04:10 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4436 label Biography information for Cat Smith

1700280

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Chronic Fatigue Syndrome: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to ensure hospitals develop treatment pathways for Myalgic encephalomyelitis or chronic fatigue syndrome patients at risk of starvation.
	tabling member constituency	Lancaster and Fleetwood
	tabling member printed	Cat Smith
	uin	21116
	answer	answer is ministerial correction date of answer 17/04/2024 answer text <p>It is the duty of clinicians to keep themselves appraised of best practice, in particular guidance issued by the National Institute for Health and Care Excellence (NICE). The Department is working with NHS England to develop an e-learning course on myalgic encephalomyelitis (ME), also known as chronic fatigue syndrome, for healthcare professionals, with the aim of supporting staff in providing better care and improving patient outcomes. This has involved feedback and input from the ME Research Collaborative Patient Advisory Group. The Medical Schools Council will promote the NHS England e-learning package on ME to all United Kingdom medical schools, and encourage medical schools to provide undergraduates with direct patient experience of ME. The NICE’s guidance NG206 states that people with ME should undertake a dietetic assessment by a dietitian with a special interest in ME, if they are losing weight and at risk of malnutrition.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 21115 question first answered 17/04/2024 14:04:11 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4436 label Biography information for Cat Smith

1700334

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Breast Cancer: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether her Department has made a recent assessment of the potential merits of using breast density assessment software at women's first breast cancer screening appointments; and if she will make an assessment of the potential impact of that technology on women's awareness of their personal risk of developing breast cancer.
	tabling member constituency	North Warwickshire
	tabling member printed	Craig Tracey
	uin	21156
	answer	answer is ministerial correction date of answer 16/04/2024 answer text <p>The Breast Screening Risk Adaptive Imaging for Density trial is looking into the use of supplementary imaging techniques for women, within the standard breast screening programme, who are found to have radiographically dense breast tissue. The UK National Screening Committee, which advises ministers and the National Health Service in all four countries in the United Kingdom, will review this evidence when it becomes available.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 16/04/2024 10:56:31 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4509 label Biography information for Craig Tracey

1700362

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Breast Cancer: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps she is taking to support women with a genetic history of breast cancer to access screening services in (a) England and (b) Leicestershire.
	tabling member constituency	Bosworth
	tabling member printed	Dr Luke Evans
	uin	21249
	answer	answer is ministerial correction date of answer 18/04/2024 answer text <p>In Leicestershire and nationwide, women with a very high risk (VHR) of breast cancer due to family history may be offered screening earlier and more often, as part of the NHS Breast Screening Programme.</p><p>Women formally identified as eligible for VHR breast screening are referred to the National Health Service breast screening service associated with their general practice. They are eligible to be screened from the age of 25 years old upwards, and should be invited every year. The diagnostic screen includes mammography or magnetic resonance imaging, depending on age and risk criteria, and is therefore not the same as the routine breast screening service. To support screening of VHR women, a new central database is planned to ensure all referrals reach NHS breast screening services.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 18/04/2024 14:59:30 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4781 label Biography information for Dr Luke Evans

1700510

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if she will make it her policy to allow pharmacies to sell vitamin B12 injections.
	tabling member constituency	Loughborough
	tabling member printed	Jane Hunt
	uin	21397
	answer	answer is ministerial correction date of answer 16/04/2024 answer text <p>To make a medicinal product available for sale in a pharmacy without a prescription, the product must be reclassified to pharmacy only status, also known as [P] medicines, by the Medicines and Healthcare products Regulatory Agency (MHRA).</p><p>This process is triggered by an application submitted to the MHRA by a company which holds a licence for the particular product. The MHRA will consider all submitted applications, with a decision to reclassify a medicine reached following a robust evaluation of the relevant data, including evidence of the safe use and supply of the product without a prescription. The company must also demonstrate in their application that the criteria specified in relevant legislation, such as the Human Medicines Regulations 2012, have been met.</p><p>In accordance with the Human Medicines Regulations 2012, regulation 62(3), Prescription-Only Medicine status will apply where: a direct or indirect danger exists to human health, even when used correctly, if used without medical supervision; there is frequently incorrect use, which could lead to direct or indirect danger to human health; further investigation of the activity or side-effects is required; or the product is normally prescribed for parenteral administration, via injection.</p><p>Currently, United Kingdom law specifies that all products administered by injection must be subject to a prescription. The MHRA is therefore unable to reclassify the status of injections, including Vitamin B12, to [P] medicines, as this would not be consistent with the legislation.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 16/04/2024 11:03:29 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4839 label Biography information for Jane Hunt

1700541

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pregnancy: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 28 April 2021 to Question 185893 on Pregnancy: Screening, on what date the evaluative rollout of non-invasive prenatal testing is expected to be completed.
	tabling member constituency	St Albans
	tabling member printed	Daisy Cooper
	uin	21428
	answer	answer is ministerial correction date of answer 17/04/2024 answer text <p>A non-invasive pre-natal test (NIPT) was introduced as an evaluative rollout in England on 1 July 2021, as part of the NHS Fetal Anomaly Screening Programme. The UK National Screening Committee (UK NSC) is being kept informed annually on the progress of this rollout.</p><p>NHS England has extended the evaluative rollout of the NIPT to March 2026, so that pregnancy outcomes can be included in the final report. The report is expected to go to the UK NSC at the end of 2026.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 17/04/2024 09:04:14 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4769 label Biography information for Daisy Cooper

1700570

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Neurodiversity: Women
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if she will commission research into the impact of (a) autism and (b) ADHD on women.
	tabling member constituency	Lewisham West and Penge
	tabling member printed	Ellie Reeves
	uin	21455
	answer	answer is ministerial correction date of answer 16/04/2024 answer text <p>The Department commissions research through the National Institute for Health and Care Research (NIHR). The NIHR is currently funding research to address measurement bias in the assessment of the presentation of autism in women, and to develop a new psychometric tool assessing the female-dominant phenotype of autism. The NIHR previously funded a study to improve the accuracy and efficiency of autism assessment for adults which, while not specific to women, will be relevant to their experiences of receiving a diagnosis. The NIHR has also funded research into topics that impact autistic individuals differently, for example how to adapt suicide safety plans to address self-harm, suicidal ideation, and suicide behaviours in autistic adults.</p><p>The NIHR welcomes funding applications for research into any aspect of human health, including the impact of autism and attention deficit hyperactivity disorder on women. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality. In all disease areas, the amount of NIHR funding depends on the volume and quality of scientific activity.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 16/04/2024 11:36:36 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4620 label Biography information for Ellie Reeves

1700571

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Neurodiversity: Women
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if she will commission research into the impact of hormonal changes on neurodiverse women throughout their lives.
	tabling member constituency	Lewisham West and Penge
	tabling member printed	Ellie Reeves
	uin	21456
	answer	answer is ministerial correction date of answer 16/04/2024 answer text <p>The Department commissions research through the National Institute for Health and Care Research (NIHR). The NIHR is not currently funding any specific research into the impact of hormonal changes on neurodiverse women, but welcomes funding applications for research into any aspect of human health. Applications are subject to peer review and judged in open competition, with awards being made based on the importance of the topic to patients and health and care services, value for money, and scientific quality.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 16/04/2024 11:14:48 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4620 label Biography information for Ellie Reeves

1700572

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Autism: Premenstrual Dysphoric Disorder
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if she will commission research into the reasons for which autistic women are more likely to suffer from premenstrual dysphoric disorder throughout their lives.
	tabling member constituency	Lewisham West and Penge
	tabling member printed	Ellie Reeves
	uin	21457
	answer	answer is ministerial correction date of answer 16/04/2024 answer text <p>The Department commissions research through the National Institute for Health and Care Research (NIHR). The NIHR is not currently funding any specific research to understand the reasons why autistic women are more likely to suffer from premenstrual dysphoric disorder, but welcomes funding applications for research into any aspect of human health. Applications are subject to peer review and judged in open competition, with awards being made based on the importance of the topic to patients and health and care services, value for money, and scientific quality.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 16/04/2024 11:17:41 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4620 label Biography information for Ellie Reeves

1700582

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cerebral Palsy: Children
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to help support children with cerebral palsy.
	tabling member constituency	Watford
	tabling member printed	Dean Russell
	uin	21467
	answer	answer is ministerial correction date of answer 17/04/2024 answer text <p>The National Institute for Health and Care Excellence has published a range of guidance on care and support for children and young people and adults with cerebral palsy, to support healthcare professionals and commissioners. The guidance recommends service providers develop clear pathways that allow patients with cerebral palsy access to multi-disciplinary teams, specialist neurology services and regular reviews of their clinical and functional needs.</p><p>NHS England’s Getting It Right First Time Programme aims to improve care for people with neurological conditions, including those with cerebral palsy, by reducing variation and delivering care more equitably across the country.</p><p>The majority of services for people with cerebral palsy are commissioned locally by integrated care boards, which are best placed to make decisions according to local need. Nevertheless, at a national level, the Government is working closely with NHS England to continue to improve services for people with neurological conditions, including those with cerebral palsy.</p><p>The NHS Long-term Workforce Plan (LTWP) aims to grow the number and proportion of National Health Service staff working in mental health, primary and community care. The LTWP, published in 2023, sets out an ambition to grow these roles 73% by 2036/37, including plans to increase the community workforce specifically by 3.9% each year. By growing the community workforce, we will be better able to support people to participate in daily living, including those with cerebral palsy.</p><p>As set out in the LTWP, NHS England’s ambition is that, by 2028, no child or young person will be lost in the gaps between any children’s and adult services, and that their experience of moving between services is safe, well planned and prepared for so they feel supported and empowered to make decisions about their health and social care needs. The Department is working closely with NHS England to support this work, and the Children and Young People’s Transformation Programme has developed a national framework for transition which includes the key principles of a 0-25 model of care, including for young people with cerebral palsy.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 21468 question first answered 17/04/2024 14:53:06 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4812 label Biography information for Dean Russell

1700583

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cerebral Palsy
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to help support adults with cerebral palsy.
	tabling member constituency	Watford
	tabling member printed	Dean Russell
	uin	21468
	answer	answer is ministerial correction date of answer 17/04/2024 answer text <p>The National Institute for Health and Care Excellence has published a range of guidance on care and support for children and young people and adults with cerebral palsy, to support healthcare professionals and commissioners. The guidance recommends service providers develop clear pathways that allow patients with cerebral palsy access to multi-disciplinary teams, specialist neurology services and regular reviews of their clinical and functional needs.</p><p>NHS England’s Getting It Right First Time Programme aims to improve care for people with neurological conditions, including those with cerebral palsy, by reducing variation and delivering care more equitably across the country.</p><p>The majority of services for people with cerebral palsy are commissioned locally by integrated care boards, which are best placed to make decisions according to local need. Nevertheless, at a national level, the Government is working closely with NHS England to continue to improve services for people with neurological conditions, including those with cerebral palsy.</p><p>The NHS Long-term Workforce Plan (LTWP) aims to grow the number and proportion of National Health Service staff working in mental health, primary and community care. The LTWP, published in 2023, sets out an ambition to grow these roles 73% by 2036/37, including plans to increase the community workforce specifically by 3.9% each year. By growing the community workforce, we will be better able to support people to participate in daily living, including those with cerebral palsy.</p><p>As set out in the LTWP, NHS England’s ambition is that, by 2028, no child or young person will be lost in the gaps between any children’s and adult services, and that their experience of moving between services is safe, well planned and prepared for so they feel supported and empowered to make decisions about their health and social care needs. The Department is working closely with NHS England to support this work, and the Children and Young People’s Transformation Programme has developed a national framework for transition which includes the key principles of a 0-25 model of care, including for young people with cerebral palsy.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 21467 question first answered 17/04/2024 14:53:06 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4812 label Biography information for Dean Russell

1700591

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pharmacy
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to help community pharmacies with increases in the cost of medications.
	tabling member constituency	St Albans
	tabling member printed	Daisy Cooper
	uin	21476
	answer	answer is ministerial correction date of answer 18/04/2024 answer text <p>The Drug Tariff, published monthly, sets out the amount that will be paid to contractors for National Health Services in England, including both product reimbursement and service remuneration.</p><p>Where pharmacies cannot purchase products at or below the Drug Tariff NHS reimbursement price, Community Pharmacy England can request that the Department reassesses the reimbursement price. If a new reimbursement price is issued within the month, this is known as a concessionary price.</p><p>In addition, from 1 April 2024, we introduced a new retrospective top-up payment for concessionary prices, providing an additional payment to contractors when the margin survey indicates that despite a concessionary price, there was an under payment.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 18/04/2024 14:49:53 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4769 label Biography information for Daisy Cooper

1700592

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Diabetes: Eating Disorders
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to NHS England's web page entitled Diabetes treatment and care programme, whether all eight Type 1 diabetes and disordered eating pilots have been commissioned by their Integrated Care Systems to secure services independently of NHS England pilot scheme funding.
	tabling member constituency	St Albans
	tabling member printed	Daisy Cooper
	uin	21477
	answer	answer is ministerial correction date of answer 19/04/2024 answer text <p>The national approach to funding the establishment of Type 1 Diabetes with Disordered Eating services was delivered in two phases. Initial sites in London, Hampshire, and Dorset received national funding between 2018/19 and 2021/22, before the transition of commissioning responsibility to local systems commenced from April 2023. All three of these services did initially secure local funding, independent of the national pilot scheme. More recently, we understand that the status of these sites to be as follows: London services are partially active across London, with local consideration of ongoing funding and delivery arrangements underway; Hampshire services are active and embedded in wider eating disorder specialist services; and Dorset services have been discontinued. The remaining five newer services have been funded from September 2022, and are nationally funded up to March 2025.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 19/04/2024 10:28:22 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4769 label Biography information for Daisy Cooper

1700593

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Diabetes: Eating Disorders
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether she has received representations from (a) healthcare professionals, (b) patient advocacy groups and (c) local authorities on discontinuing Type 1 diabetes and disordered eating services.
	tabling member constituency	St Albans
	tabling member printed	Daisy Cooper
	uin	21478
	answer	answer is ministerial correction date of answer 18/04/2024 answer text <p>My Rt hon. Friend, the Secretary of State for Health and Social Care engages with a range of external stakeholders, including discussions on Type 1 Diabetes with Disordered Eating (T1DE) services. NHS England is working closely with regional and integrated care board (ICB) level teams to ensure that informed decisions are made about the future provision of T1DE services.</p><p> </p><p>Responsibility for the commissioning of T1DE services sits with the ICBs. It is the role of local ICB decision makers to consider the implications of continuing or discontinuing T1DE services, specific to each location, and including the perspectives of healthcare professionals, patient advocacy groups, and local authorities.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 18/04/2024 14:56:08 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4769 label Biography information for Daisy Cooper

1700605

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Prosthetics
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if she will make an assessment of the adequacy of the supply of prostheses to NHS patients.
	tabling member constituency	Stockport
	tabling member printed	Navendu Mishra
	uin	21490
	answer	answer is ministerial correction date of answer 18/04/2024 answer text <p>NHS England commissions 35 prosthetic centres in England to provide specialised prosthetic services. NHS England completed a Prosthetic Services Review between 2018 and 2022, which was paused during the COVID-19 pandemic. The recommendations from the review have been incorporated within the service specification, Complex Disability Equipment – Prosthetic Specialised Services For People Of All Ages With Limb Loss, which has been updated in line with the service Specification Methods process, and will be subject to stakeholder testing during April 2024.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 18/04/2024 09:31:49 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4811 label Biography information for Navendu Mishra

1700607

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Hospitals: Parking
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if she will make an assessment of the adequacy of the number of parking spaces designated for disabled people at NHS hospitals.
	tabling member constituency	Liverpool, Walton
	tabling member printed	Dan Carden
	uin	21492
	answer	answer is ministerial correction date of answer 17/04/2024 answer text <p>Disabled blue badge holders are entitled to free hospital car parking in line with the Government’s commitment to provide free hospital car parking for those with the greatest need. Disabled patients and visitors receive free parking for the duration of their attendance at, or visit to, the hospital. Disabled employees receive free parking while at the hospital, for purposes relating to their employment.</p><p>National Health Service organisations decide locally on the provision and type of car parking spaces, in line with the policy set out by the Department, which is available at the following link:</p><p><a href="https://www.gov.uk/government/publications/nhs-patient-visitor-and-staff-car-parking-principles/nhs-patient-visitor-and-staff-car-parking-principles" target="_blank">https://www.gov.uk/government/publications/nhs-patient-visitor-and-staff-car-parking-principles/nhs-patient-visitor-and-staff-car-parking-principles</a></p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 17/04/2024 13:32:18 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4651 label Biography information for Dan Carden

1698892

	registered interest
	date	26/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Anaesthesia Associates and Physician Associates
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent discussions she has had with the General Medical Council on (a) regulating (i) physician and (ii) anaesthesia associates and (b) ensuring that increased use of these roles in hospitals does not impact (A) the professional competence of other healthcare professionals and (B) patient safety.
	tabling member constituency	York Central
	tabling member printed	Rachael Maskell
	uin	20681
	answer	answer is ministerial correction date of answer 15/04/2024 answer text <p>The Department has been working closely with the General Medical Council (GMC) since 2019, on the regulation of Anaesthesia Associates (AAs) and Physician Associates (PAs). Regulation with the GMC will provide set standards of practice, education, and training for AAs and PAs, as well as requirements around continual professional development (CPD) and conduct. Regulation with the GMC will mean that individual AAs and PAs can be held to account if serious concerns are raised.</p><p> </p><p>The NHS Long Term Workforce Plan commits to growing these roles alongside recruiting and training more doctors, nurses, and allied health and other professionals. NHS England is working with partners, including the GMC, royal colleges, trade unions, doctors, and medical associate professional groups to develop comprehensive curricula, core capability frameworks, standards for CPD, assessment and appraisal, and supervision guidance for AAs and PAs, ensuring the roles are expanded safely and effectively.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 15/04/2024 08:29:10 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4471 label Biography information for Rachael Maskell

1698899

	registered interest
	date	26/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Health Professions
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what discussions she is having with professional bodies on ensuring that the public have a clear understanding of (a) professional titles and (b) the services they can expect from the holders of such titles.
	tabling member constituency	York Central
	tabling member printed	Rachael Maskell
	uin	20682
	answer	answer is ministerial correction date of answer 15/04/2024 answer text <p>It is the responsibility of professionals and their employers to ensure professional titles are used appropriately, and are not misleading to patients. National Institute for Health and Care Excellence (NICE) guidelines set out that all healthcare professionals directly involved in a patient's care should introduce themselves and explain to the patient: who is responsible for their clinical care and treatment; the roles and responsibilities of the different members of the healthcare team; and the communication about their care that takes place between members of the healthcare team.</p><p> </p><p>Professions that are regulated in statute have titles that are protected by law, and professionals must be registered with a statutory regulator to use them. It is an offence for a person to use a title they are not legally permitted to use, or to otherwise hold themselves out to be a regulated professional.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 15/04/2024 08:28:46 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4471 label Biography information for Rachael Maskell

1698924

	registered interest
	date	26/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS Greater Manchester: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, when she last met with Greater Manchester NHS Board to discuss the statutory commissioning of NICE approved medicines.
	tabling member constituency	Makerfield
	tabling member printed	Yvonne Fovargue
	uin	20611
	answer	answer is ministerial correction date of answer 15/04/2024 answer text <p>Ministers have not met with Greater Manchester NHS Board about the statutory commissioning of National Institute for Health and Care Excellence (NICE) recommended medicines. Similarly I am informed that NHS England is not aware of any such discussions.</p><p>The National Health Service in England is legally required to make funding available for treatments recommended in NICE technology appraisal and highly specialised technologies guidance, normally within three months of the publication of final guidance. This requirement is reflected in the NHS Constitution as a right to drugs and treatments that have been recommended by NICE for use in the NHS, if their doctor believes they are clinically appropriate.</p><p>The NHS Standard Contract is mandated by NHS England for use by commissioners for all contracts for healthcare services other than primary care. The 2024/25 standard contract states that, where any service involves or may involve the prescribing of medicines, the provider must ensure that its formulary reflects all relevant positive NICE technology appraisals. NICE’s guideline on developing and updating local formularies states that when a NICE technology appraisal recommends a medicine, it should be adopted into the local formulary automatically if clinically appropriate and relevant to the services provided by the organisation, and that this process should take place within three months.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20612 20613 question first answered 15/04/2024 08:04:14 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4034 label Biography information for Yvonne Fovargue

1698925

	registered interest
	date	26/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS Greater Manchester: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what discussions NHS England have had with Greater Manchester NHS on their statutory responsibilities to commission NICE approved medicines.
	tabling member constituency	Makerfield
	tabling member printed	Yvonne Fovargue
	uin	20612
	answer	answer is ministerial correction date of answer 15/04/2024 answer text <p>Ministers have not met with Greater Manchester NHS Board about the statutory commissioning of National Institute for Health and Care Excellence (NICE) recommended medicines. Similarly I am informed that NHS England is not aware of any such discussions.</p><p>The National Health Service in England is legally required to make funding available for treatments recommended in NICE technology appraisal and highly specialised technologies guidance, normally within three months of the publication of final guidance. This requirement is reflected in the NHS Constitution as a right to drugs and treatments that have been recommended by NICE for use in the NHS, if their doctor believes they are clinically appropriate.</p><p>The NHS Standard Contract is mandated by NHS England for use by commissioners for all contracts for healthcare services other than primary care. The 2024/25 standard contract states that, where any service involves or may involve the prescribing of medicines, the provider must ensure that its formulary reflects all relevant positive NICE technology appraisals. NICE’s guideline on developing and updating local formularies states that when a NICE technology appraisal recommends a medicine, it should be adopted into the local formulary automatically if clinically appropriate and relevant to the services provided by the organisation, and that this process should take place within three months.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20611 20613 question first answered 15/04/2024 08:04:14 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4034 label Biography information for Yvonne Fovargue

1698926

	registered interest
	date	26/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Medical Treatments: Technology
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what guidance her Department issues NHS trusts on establishing commissioning structures for Health Technology Assessments; and whether trusts have discretion to adopt different processes.
	tabling member constituency	Makerfield
	tabling member printed	Yvonne Fovargue
	uin	20613
	answer	answer is ministerial correction date of answer 15/04/2024 answer text <p>Ministers have not met with Greater Manchester NHS Board about the statutory commissioning of National Institute for Health and Care Excellence (NICE) recommended medicines. Similarly I am informed that NHS England is not aware of any such discussions.</p><p>The National Health Service in England is legally required to make funding available for treatments recommended in NICE technology appraisal and highly specialised technologies guidance, normally within three months of the publication of final guidance. This requirement is reflected in the NHS Constitution as a right to drugs and treatments that have been recommended by NICE for use in the NHS, if their doctor believes they are clinically appropriate.</p><p>The NHS Standard Contract is mandated by NHS England for use by commissioners for all contracts for healthcare services other than primary care. The 2024/25 standard contract states that, where any service involves or may involve the prescribing of medicines, the provider must ensure that its formulary reflects all relevant positive NICE technology appraisals. NICE’s guideline on developing and updating local formularies states that when a NICE technology appraisal recommends a medicine, it should be adopted into the local formulary automatically if clinically appropriate and relevant to the services provided by the organisation, and that this process should take place within three months.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20611 20612 question first answered 15/04/2024 08:04:14 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4034 label Biography information for Yvonne Fovargue

1698943

	registered interest
	date	26/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS England: Equality
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many people are employed by NHS England in roles relating to equality, diversity and inclusivity as of 26 March 2024.
	tabling member constituency	South Holland and The Deepings
	tabling member printed	Sir John Hayes
	uin	20512
	answer	answer is ministerial correction date of answer 15/04/2024 answer text <p>There are 51 staff with equality, diversity, or inclusion in their job title at NHS England, as of 26 February 2024. This covers a wide range of roles both supporting NHS England as an employer, and facing the wider National Health Service system, with some of these roles also covering other areas of NHS policy. NHS England has reduced the number of roles focused on equality, diversity and inclusion as part of its merger with NHS Digital and Health Education England. The roles that remain are essential to helping the NHS meet its legal duties in the Equality Act 2010 and the principles that guide the NHS Constitution. This includes overseeing statutory programmes that are focused on tackling discrimination by some staff which includes disabled staff, as well as roles dealing with the sexual safety of staff and patients in the NHS.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 15/04/2024 08:56:23 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	350 label Biography information for Sir John Hayes

1698967

	registered interest
	date	26/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Staff
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, when she plans to publish details on how the NHS long-term workforce plan will be implemented.
	tabling member constituency	Bootle
	tabling member printed	Peter Dowd
	uin	20659
	answer	answer is ministerial correction date of answer 15/04/2024 answer text <p>We have established a Long Term Workforce Plan Governance Board which will ensure the delivery and review the progress of the Long Term Workforce Plan’s implementation. The modelling NHS England has used in the plan is founded on data, evidence, and analysis and provides a set of broad ranges to measure the potential impact of actions over its 15 year timeframe. We have committed to refreshing the modelling that underpins the plan every two years, or in line with fiscal events.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20625 question first answered 15/04/2024 08:17:19 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4397 label Biography information for Peter Dowd

1698968

	registered interest
	date	26/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Parkinson's Disease: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether the NHS Long Term Workforce Plan will include steps to help tackle regional variations in access to Parkinson’s specialist care.
	tabling member constituency	Bootle
	tabling member printed	Peter Dowd
	uin	20660
	answer	answer is ministerial correction date of answer 15/04/2024 answer text <p>The NHS Long Term Workforce Plan (LTWP) sets out the steps the National Health Service and its partners need to take to deliver an NHS workforce that meets the changing needs of the population over the next 15 years. It covers the majority of NHS workforce groups, including those working on Parkinson’s disease. The LTWP commits to working closely with systems to consider the best approaches to reviewing the geographical distribution of training posts for wider professional groups.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20628 question first answered 15/04/2024 08:18:31 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4397 label Biography information for Peter Dowd

1698988

	registered interest
	date	26/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Staff
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, when she plans to publish further information on the implementation of the NHS long-term workforce plan.
	tabling member constituency	North Tyneside
	tabling member printed	Mary Glindon
	uin	20625
	answer	answer is ministerial correction date of answer 15/04/2024 answer text <p>We have established a Long Term Workforce Plan Governance Board which will ensure the delivery and review the progress of the Long Term Workforce Plan’s implementation. The modelling NHS England has used in the plan is founded on data, evidence, and analysis and provides a set of broad ranges to measure the potential impact of actions over its 15 year timeframe. We have committed to refreshing the modelling that underpins the plan every two years, or in line with fiscal events.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20659 question first answered 15/04/2024 08:17:19 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4126 label Biography information for Mary Glindon

1699006

	registered interest
	date	26/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Parkinson's Disease: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if she will amend the NHS long-term workforce plan to help tackle regional variations in access to Parkinson’s specialist care.
	tabling member constituency	North Tyneside
	tabling member printed	Mary Glindon
	uin	20628
	answer	answer is ministerial correction date of answer 15/04/2024 answer text <p>The NHS Long Term Workforce Plan (LTWP) sets out the steps the National Health Service and its partners need to take to deliver an NHS workforce that meets the changing needs of the population over the next 15 years. It covers the majority of NHS workforce groups, including those working on Parkinson’s disease. The LTWP commits to working closely with systems to consider the best approaches to reviewing the geographical distribution of training posts for wider professional groups.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20660 question first answered 15/04/2024 08:18:31 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4126 label Biography information for Mary Glindon

1699131

	registered interest
	date	26/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Whooping Cough: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether she is taking steps to ensure adequate supplies of pertussis vaccine in the context of the rise in instances in the Czech Republic.
	tabling member constituency	Slough
	tabling member printed	Mr Tanmanjeet Singh Dhesi
	uin	20743
	answer	answer is ministerial correction date of answer 15/04/2024 answer text <p>The UK Health Security Agency (UKHSA) centrally procures and manages the United Kingdom’s supply of the pertussis vaccine, for the routine national immunisation programmes. Due to the stockpiles maintained in the UK for the national programme, there is good supply available of all pertussis-containing vaccines for the routine immunisation programmes.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 15/04/2024 08:47:34 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4638 label Biography information for Mr Tanmanjeet Singh Dhesi

1699132

	registered interest
	date	26/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Health Services: Technology
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether she has received representations of concern from (a) patient safety groups and (b) medical equipment suppliers on the interim methods and processes statement for late-stage assessments published by NICE.
	tabling member constituency	St Albans
	tabling member printed	Daisy Cooper
	uin	20775
	answer	answer is ministerial correction date of answer 15/04/2024 answer text <p>The National Institute for Health and Care Excellence’s (NICE) interim methods and processes for late-stage assessment have been subject to a public consultation between 29 February and 28 March 2024. The consultation allowed stakeholders from across the sector, including medical equipment suppliers, patients, and caregivers, to comment on these interim methods and processes. This included the proposed use of predetermined price ranges for categories of technologies. The Department and the NICE are unable to comment on the results of the consultation at this stage, as the NICE is currently considering the responses. Further information will be made available upon the completion of this process.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20777 question first answered 15/04/2024 08:43:00 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4769 label Biography information for Daisy Cooper